Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kristina Kriksciukaite
Observed name:
K. Kriksciukaite
Institution:
Tarveda Therapeutics (United States)
Observed institutions:
Alkermes (United States),
Tarveda Therapeutics (United States)
OpenAlex ID:
A5042589429
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2019
·
Kerry A. Whalen
, Brian H. White
, et al.
·
Molecular Cancer Therapeutics
·
81
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo
2019
·
Brian H. White
, Kerry Whalen
, et al.
·
Journal of Medicinal Chemistry
·
58
Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results.
2020
·
Gerald Steven Falchook
, Johanna C. Bendell
, et al.
·
Journal of Clinical Oncology
·
32
Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone
2008
·
Reginald L. Dean
, Mark S. Todtenkopf
, et al.
·
Pharmacology Biochemistry and Behavior
·
31
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.
2018
·
Melissa Lynne Johnson
, Tim Meyer
, et al.
·
Journal of Clinical Oncology
·
26
The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.
2021
·
Daniel M. Halperin
, Melissa Lynne Johnson
, et al.
·
Journal of Clinical Oncology
·
21
The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate
2013
·
Pui Ng
, Jean Bemis
, et al.
·
Letters in Drug Design & Discovery
·
21
PRECLINICAL STUDY: Route of administration affects the ability of naltrexone to reduce amphetamine‐potentiated brain stimulation reward in rats
2009
·
Mark S. Todtenkopf
, Krystal S. O'Neill
, et al.
·
Addiction Biology
·
18
Simple Method Provides Resolution of Albumin, Lipoprotein, Free Fraction, and Chylomicron To Enhance the Utility of Protein Binding Assays
2015
·
Adam H. Brockman
, Haley R. Oller
, et al.
·
Journal of Medicinal Chemistry
·
14
First in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumours: Phase I results
2019
·
J.C. Bendell
, G. Falchook
, et al.
·
Annals of Oncology
·
11
Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2020
·
Samantha Perino
, Benoit Moreau
, et al.
·
Molecular Cancer Therapeutics
·
10
PDF
Abstract CT156: Characterization of PEN-866, a Heat Shock Protein 90 (HSP90) binding conjugate of SN-38, in patient plasma and tumors from the first in human study
2020
·
Anish Thomas
, Kristina Kriksciukaite
, et al.
·
Cancer Research
·
6
Abstract 4484: BTP-114: An albumin binding cisplatin prodrug with improved and sustained tumor growth inhibition
2015
·
Benoit Moreau
, Rossitza Alargova
, et al.
·
Cancer Research
·
5
Abstract 3674: Pentarins: Improved tumor targeting through nanoparticle encapsulation of miniaturized biologic drug conjugates
2015
·
Mark T. Bilodeau
, Rajesh Shinde
, et al.
·
Cancer Research
·
5
Abstract 39: Discovery of PEN-221, an SSTR2-targeting maytansinoid conjugate with potent activity in vitro and in vivo
2017
·
Brian H. White
, Patrick Bazinet
, et al.
·
Cancer Research
·
3
Simple Method Provides Resolution of Albumin, Lipoprotein, Free Fraction, and Chylomicron to Enhance the Utility of Protein Binding Assays
2015
·
Adam Brockman
, Haley Oller
, et al.
·
The FASEB Journal
·
1
Supplemental Materials and Methods from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023
·
Kerry A. Whalen
, Brian H. White
, et al.
Supplemental Table S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023
·
Kerry A. Whalen
, Brian H. White
, et al.
Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023
·
Kerry A. Whalen
, Brian H. White
, et al.
Supplemental Figure S4 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023
·
Kerry A. Whalen
, Brian H. White
, et al.
Supplemental Table S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023
·
Kerry A. Whalen
, Brian H. White
, et al.
Supplemental Figure S3 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023
·
Kerry A. Whalen
, Brian H. White
, et al.
Supplemental Figure S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023
·
Kerry A. Whalen
, Brian H. White
, et al.
Supplementary Figure 3 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023
·
Samantha Perino
, Benoit Moreau
, et al.
Supplementary Synthesis Route from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023
·
Samantha Perino
, Benoit Moreau
, et al.
Show more works
View as search
Works count:
39
Citation count:
343
H-index:
10
I10-index:
11
Year
Topic
Type